EA201690926A1 - Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек - Google Patents

Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек

Info

Publication number
EA201690926A1
EA201690926A1 EA201690926A EA201690926A EA201690926A1 EA 201690926 A1 EA201690926 A1 EA 201690926A1 EA 201690926 A EA201690926 A EA 201690926A EA 201690926 A EA201690926 A EA 201690926A EA 201690926 A1 EA201690926 A1 EA 201690926A1
Authority
EA
Eurasian Patent Office
Prior art keywords
iron
increase
patients
iii
reduce
Prior art date
Application number
EA201690926A
Other languages
English (en)
Russian (ru)
Inventor
Энрике Порадосу
Рон Бентсур
Джеймс Ф. Оливьеро III
Original Assignee
Керикс Байофармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Керикс Байофармасьютикалз, Инк. filed Critical Керикс Байофармасьютикалз, Инк.
Publication of EA201690926A1 publication Critical patent/EA201690926A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EA201690926A 2013-11-04 2014-11-03 Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек EA201690926A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
PCT/US2014/063643 WO2015066593A1 (en) 2013-11-04 2014-11-03 Ferric citrate for reducing cardiac failure in chronic kidney disease patients

Publications (1)

Publication Number Publication Date
EA201690926A1 true EA201690926A1 (ru) 2016-09-30

Family

ID=53005244

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690926A EA201690926A1 (ru) 2013-11-04 2014-11-03 Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек

Country Status (15)

Country Link
US (3) US20160256486A1 (https=)
EP (2) EP3747432A1 (https=)
JP (3) JP2016535780A (https=)
KR (1) KR102392441B1 (https=)
CN (1) CN105873583A (https=)
AU (1) AU2014341975A1 (https=)
BR (1) BR112016009901A8 (https=)
CA (1) CA2928200A1 (https=)
EA (1) EA201690926A1 (https=)
HK (1) HK1223031A1 (https=)
IL (1) IL245317A0 (https=)
MX (1) MX2016005734A (https=)
SG (1) SG11201603091QA (https=)
TW (2) TWI744215B (https=)
WO (1) WO2015066593A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011011541A1 (en) 2009-07-21 2011-01-27 Henry Trong Le Ferric citrate dosage forms
EP3003327B1 (en) 2013-06-05 2017-08-09 Tricida Inc. Proton-binding polymers for oral administration
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
RS61409B1 (sr) 2014-12-10 2021-03-31 Tricida Inc Polimeri koji vezuju protone za oralnu primenu opis
CN109414453B (zh) 2016-05-06 2023-02-17 特里赛达公司 用于治疗酸碱失衡的组合物
CA3080651A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
MX2021004640A (es) 2018-10-29 2021-05-28 Pharmacosmos Holding As Tratamiento de la deficiencia de hierro con carboximaltosa ferrica.
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
EP4347022A1 (en) * 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (https=) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
CA2619591C (en) * 2005-08-18 2020-03-24 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
KR20080106506A (ko) * 2006-01-30 2008-12-08 글로보아시아 엘엘씨 만성 신장병의 치료 방법
JP2009525277A (ja) * 2006-01-30 2009-07-09 グロボアジア エルエルシー 軟組織石灰化の回復、予防、遅延または安定化方法
WO2011011541A1 (en) * 2009-07-21 2011-01-27 Henry Trong Le Ferric citrate dosage forms
WO2012006473A1 (en) * 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US20130345303A1 (en) * 2012-06-21 2013-12-26 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of chronic kidney disease patients

Also Published As

Publication number Publication date
TW201609088A (zh) 2016-03-16
US20250360167A1 (en) 2025-11-27
TWI744215B (zh) 2021-11-01
CA2928200A1 (en) 2015-05-07
EP3065734A4 (en) 2017-05-17
SG11201603091QA (en) 2016-05-30
HK1223031A1 (zh) 2017-07-21
WO2015066593A1 (en) 2015-05-07
EP3747432A1 (en) 2020-12-09
AU2014341975A1 (en) 2016-05-19
JP2021073230A (ja) 2021-05-13
JP2016535780A (ja) 2016-11-17
KR20160096597A (ko) 2016-08-16
US20160256486A1 (en) 2016-09-08
EP3065734A1 (en) 2016-09-14
CN105873583A (zh) 2016-08-17
JP2019206562A (ja) 2019-12-05
IL245317A0 (en) 2016-06-30
US20190307791A1 (en) 2019-10-10
KR102392441B1 (ko) 2022-05-02
MX2016005734A (es) 2016-11-08
BR112016009901A8 (pt) 2020-04-14
JP6828100B2 (ja) 2021-02-10
TW202203910A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
EA201690926A1 (ru) Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек
MX2014015615A (es) Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica.
EA201590849A1 (ru) Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови
MX2017010734A (es) Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
MX2019006259A (es) Transporte para atravesar la barrera hematoencefalica.
BR112015025955A2 (pt) tratamentos anticancerosos com anticorpos anti-egfr apresentando uma baixa fucosilação
EA201591762A1 (ru) Человеческие антитела к grem1
EA201591424A1 (ru) Способы лечения дефицита железа растворимым пирофосфатом железа
Chavez et al. New insights into the regulation of vascular permeability
MX2020011190A (es) Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension.
EA201590883A1 (ru) Лечение помалидомидом рака у субъекта с почечной недостаточностью
PE20141577A1 (es) Espray para heridas
EA201500363A1 (ru) Человеческие анти-vegfr-2/kdr-антитела
EA201791611A1 (ru) Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида
PH12015502301A1 (en) Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
EA201891533A1 (ru) Способы и композиции для лечения синдрома хантера
EA202090028A1 (ru) Способы уменьшения или предотвращения сердечно-сосудистых явлений у пациентов с сахарным диабетом ii типа
EA201790790A1 (ru) Антитела человека против vegfr-2/kdr
RU2013155841A (ru) Способ ранней диагностики хронической болезни почек
BR112014032781A2 (pt) dispositivo para aumentar fluxo sanguíneo, perfusão tecidual e distribuição de fluidos por estimulação neuromuscular em cavalos e outros mamíferos não-humanos
UA62757U (ru) Способ прогнозирования адекватности программного гемодиализа у больных с хронической болезнью почек v стадии
RU2013110191A (ru) Способ определения предикторной значимости мозгового натрийуретического пептида у больных хронической болезнью почек, получающих терапию программным гемодиализом
Chairkin et al. CHANGE IN THE STRUCTURE OF THE ADRENAL CORTEX ON THE FIRST DAY AFTER ACUTE BLOOD LOSS